Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)
Publication
, Journal Article
Bradley, DA; Daignault, S; Ryan, CJ; DiPaola, RS; Cooney, KA; Smith, DC; Small, E; Mathew, P; Gross, ME; Stein, MN; Chen, A; Pienta, KJ ...
Published in: Investigational New Drugs
December 1, 2011
Duke Scholars
Published In
Investigational New Drugs
DOI
EISSN
1573-0646
ISSN
0167-6997
Publication Date
December 1, 2011
Volume
29
Issue
6
Start / End Page
1517 / 1518
Related Subject Headings
- Oncology & Carcinogenesis
- 3214 Pharmacology and pharmaceutical sciences
- 3211 Oncology and carcinogenesis
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Bradley, D. A., Daignault, S., Ryan, C. J., DiPaola, R. S., Cooney, K. A., Smith, D. C., … Hussain, M. (2011). Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs, 29(6), 1517–1518. https://doi.org/10.1007/s10637-010-9502-7
Bradley, D. A., S. Daignault, C. J. Ryan, R. S. DiPaola, K. A. Cooney, D. C. Smith, E. Small, et al. “Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8).” Investigational New Drugs 29, no. 6 (December 1, 2011): 1517–18. https://doi.org/10.1007/s10637-010-9502-7.
Bradley DA, Daignault S, Ryan CJ, DiPaola RS, Cooney KA, Smith DC, et al. Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs. 2011 Dec 1;29(6):1517–8.
Bradley, D. A., et al. “Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8).” Investigational New Drugs, vol. 29, no. 6, Dec. 2011, pp. 1517–18. Scopus, doi:10.1007/s10637-010-9502-7.
Bradley DA, Daignault S, Ryan CJ, DiPaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs. 2011 Dec 1;29(6):1517–1518.
Published In
Investigational New Drugs
DOI
EISSN
1573-0646
ISSN
0167-6997
Publication Date
December 1, 2011
Volume
29
Issue
6
Start / End Page
1517 / 1518
Related Subject Headings
- Oncology & Carcinogenesis
- 3214 Pharmacology and pharmaceutical sciences
- 3211 Oncology and carcinogenesis
- 1115 Pharmacology and Pharmaceutical Sciences